Nicox and Glaukos Sign Exclusive NCX 1728 Research and Worldwide License Agreement

Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), a global ophthalmology company, today announced that it has entered into an exclusive research and license option agreement with Glaukos Corporation for NCX 1728, Nicox’s novel nitric oxide (NO)-donating phosphodiesterase-5 (PDE5) inhibitor. Glaukos is an American ophthalmology pharmaceutical and medical device company focused on novel therapies for the treatment of glaucoma, corneal diseases and retinal diseases.

“Glaukos has expertise in treating ophthalmic diseases and unique drug delivery capabilities that may optimize NCX 1728 for applications such as intraocular pressure reduction, neuroprotection and as a potential treatment for retinal diseases. Glaukos is therefore an ideal partner to accelerate the research and development of this unique compound and realize its therapeutic potential. We look forward to working with Glaukos to evaluate the use of this novel molecule in multiple different indications.” said Doug Hubatsch, Chief Scientific Officer of Nicox.

Under the terms of the agreement, Glaukos will fund the evaluation of NCX 1728 in a preclinical research program agreed between Nicox and Glaukos. The program will investigate indications for the treatment of glaucoma, including neuroprotection, and in the treatment of retinal diseases, with activities overseen by a Joint Steering Committee. Glaukos has an option to license NCX 1728 on an exclusive worldwide basis for development in these ophthalmic indications, exercisable within certain specified time periods, the first of which is in 12 months.